SAN DIEGO, Feb. 10, 2026 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced it will release its fourth quarter and full year 2025 financial and operating results on Tuesday, February 17, 2026, following the close of trading. Halozyme will host a…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
